DE4090565T - - Google Patents

Info

Publication number
DE4090565T
DE4090565T DE19904090565 DE4090565T DE4090565T DE 4090565 T DE4090565 T DE 4090565T DE 19904090565 DE19904090565 DE 19904090565 DE 4090565 T DE4090565 T DE 4090565T DE 4090565 T DE4090565 T DE 4090565T
Authority
DE
Germany
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE19904090565
Other languages
German (de)
Other versions
DE4090565C2 (de
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of DE4090565T publication Critical patent/DE4090565T/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/02—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using fungi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE19904090565 1989-04-17 1990-04-16 Pending DE4090565T (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33900489A 1989-04-17 1989-04-17
US39448889A 1989-08-16 1989-08-16
US07/502,834 US5338683A (en) 1981-12-24 1990-04-04 Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins

Publications (1)

Publication Number Publication Date
DE4090565T true DE4090565T (enExample) 1992-05-14

Family

ID=27407304

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19904090565 Pending DE4090565T (enExample) 1989-04-17 1990-04-16
DE4090565A Expired - Lifetime DE4090565C2 (de) 1989-04-17 1990-04-16 Rekombinantes Herpesvirus-Pockenvirus-Vakzin

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE4090565A Expired - Lifetime DE4090565C2 (de) 1989-04-17 1990-04-16 Rekombinantes Herpesvirus-Pockenvirus-Vakzin

Country Status (17)

Country Link
US (3) US5338683A (enExample)
JP (2) JP3083839B2 (enExample)
KR (1) KR920700289A (enExample)
AT (1) AT405184B (enExample)
AU (1) AU625623B2 (enExample)
BE (1) BE1004369A5 (enExample)
CA (1) CA2014465C (enExample)
CH (1) CH682671A5 (enExample)
DE (2) DE4090565T (enExample)
DK (1) DK176464B1 (enExample)
FR (1) FR2647808B1 (enExample)
GB (1) GB2246784B (enExample)
IE (1) IE61098B1 (enExample)
IT (1) IT1241119B (enExample)
LU (1) LU88018A1 (enExample)
NL (1) NL195016C (enExample)
WO (1) WO1990012882A1 (enExample)

Families Citing this family (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US7767449B1 (en) 1981-12-24 2010-08-03 Health Research Incorporated Methods using modified vaccinia virus
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5674735A (en) * 1990-07-06 1997-10-07 University Court Of The University Of Glasgow DNA encoding the EHV-4 gH or gC glycoprotein
GB9014950D0 (en) * 1990-07-06 1990-08-29 Univ Glasgow Ehv-4 glycoprotein vaccine
US7374768B1 (en) * 1990-09-25 2008-05-20 Xenova Research Limited Viral vaccines
DK0550553T3 (da) * 1990-09-25 2000-10-23 Cantab Pharma Res Viral defekt vaccine fremstillet af en transkomplementerende cellelinie
US5759552A (en) * 1991-03-07 1998-06-02 Virogenetics Corporation Marek's disease virus recombinant poxvirus vaccine
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
EP0561034B1 (en) * 1991-08-26 1999-06-09 IMMUNO Aktiengesellschaft Direct molecular cloning of a modified chordopox virus genome
ATE253123T1 (de) * 1991-08-26 2003-11-15 Baxter Healthcare Sa Ein intaktes fpv-tk-gen enthaltender rekombinanter virus der vogelpocken
US5869312A (en) * 1992-01-13 1999-02-09 Syntro Corporation Recombinant swinepox virus
WO1994019015A1 (en) * 1993-02-26 1994-09-01 Syntro Corporation Recombinant fowlpox viruses and uses thereof
US6136318A (en) * 1993-02-26 2000-10-24 Cochran; Mark D. Recombinant fowlpox viruses and uses thereof
US5925358A (en) * 1993-02-26 1999-07-20 Syntro Corporation Recombinant fowlpox viruses and uses thereof
US6010703A (en) * 1993-07-26 2000-01-04 Board Of Trustees Operating Michigan State University Recombinant poxvirus vaccine against feline rhinotracheitis
DE69535561T2 (de) * 1994-03-30 2008-06-05 Connaught Technology Corp., Greenville NUKLEOTID- UND AMINOSÄURESEQUENZEN gB, gC UND gD DES HERPESVIRUS DES HUNDES UND IHRE VERWENDUNGEN
EP0758397B1 (en) * 1994-04-29 2005-06-22 Baxter Healthcare S.A. Recombinant poxviruses with foreign polynucleotides in essential regions
JP2002512501A (ja) 1996-07-03 2002-04-23 メリアル インコーポレイテッド 外来性ｄｎａを含む組換えイヌアデノウィルス（ｃａｖ）
US6183752B1 (en) * 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US6224882B1 (en) 1997-11-07 2001-05-01 Protein Science Corp. Insect cells or fractions as adjuvant for antigens
PT1060247E (pt) 1998-02-24 2008-12-22 Sisters Of Providence In Orego Composições que contêm um agente de ligação ao receptor ox-40 ou um ácido nucleico que codifica para o mesmo e métodos para melhorar a resposta imunitária específica do antigénio
CA2322160C (en) 1998-02-27 2013-01-29 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
WO2000049049A1 (en) 1999-02-19 2000-08-24 Michigan State University An antigen test to detect equine protozoal myeloencephalitis in horse serum and cerebrospinal fluid
CN1348332A (zh) 1999-03-03 2002-05-08 宾夕法尼亚大学理事会 疫苗和基因治疗组合物以及其制备和使用方法
CN1196495C (zh) 1999-04-30 2005-04-13 宾夕法尼亚大学理事会 突变的人cd80及其制备和应用组合物和方法
AU782154C (en) * 1999-06-10 2006-02-09 Boehringer Ingelheim Animal Health USA Inc. DNA vaccines for pets and sport animals
AU5329300A (en) 1999-06-10 2001-01-02 Michigan State University Feline calicivirus isolated from cat urine and vaccines thereof
CA2382026A1 (en) 1999-09-02 2001-03-08 Ruth A. Vrable Vaccine to control equine protozoal myeloencephalitis in horses
US7419668B1 (en) 1999-09-02 2008-09-02 Board Of Trustees Of Michigan State University Vaccine to control equine protozoal myeloencephalitis in horses
DK1248646T3 (da) * 1999-12-21 2008-05-19 Merial Sas Præparater og vacciner indeholdende antigen(er) fra cryptosporidium parvum og fra andet enterisk patogen
AU8349301A (en) * 2000-07-14 2002-01-30 Univ Pennsylvania Dna vaccines encoding hiv accessory proteins
AU1152402A (en) 2000-10-04 2002-04-15 Univ Pennsylvania Highly expressible genes
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
CA2421151C (en) 2000-11-23 2013-07-02 Bavarian Nordic A/S Modified vaccinia ankara virus variant
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US20020108132A1 (en) * 2001-02-02 2002-08-08 Avigenics Inc. Production of a monoclonal antibody by a transgenic chicken
US7176300B2 (en) * 2001-03-30 2007-02-13 Avigenics, Inc. Avian lysozyme promoter
AU2002255995A1 (en) 2001-03-30 2002-10-15 Avigenics, Inc. Avian lysozyme promoter
US7541512B2 (en) * 2001-03-30 2009-06-02 Synageva Biopharma Corp. Avians containing a lysozyme promoter transgene
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
US7740863B2 (en) * 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
US20040037848A1 (en) * 2001-04-06 2004-02-26 Audonnet Jean-Christophe Francis Recombinant vaccine against West Nile Virus
AU2002329176A1 (en) 2001-05-25 2002-12-23 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
US7550650B2 (en) * 2001-09-18 2009-06-23 Synageva Biopharma Corp. Production of a transgenic avian by cytoplasmic injection
US6875588B2 (en) 2001-11-30 2005-04-05 Avigenics, Inc. Ovomucoid promoter and methods of use
US20100333219A1 (en) * 2001-11-30 2010-12-30 Synageva Biopharma Corp. Methods of protein production using ovomucoid regulatory regions
US7335761B2 (en) * 2001-11-30 2008-02-26 Avigenics, Inc. Avian gene expression controlling regions
US7294507B2 (en) * 2001-11-30 2007-11-13 Avigenics, Inc. Ovomucoid promoters and methods of use
US7135562B2 (en) 2002-03-14 2006-11-14 University Of Cincinnati Avian iFABP gene expression controlling region
US20040241723A1 (en) * 2002-03-18 2004-12-02 Marquess Foley Leigh Shaw Systems and methods for improving protein and milk production of dairy herds
IL163701A0 (en) * 2002-04-19 2005-12-18 Bavarian Nordic As Modified vaccinia virus ankara for the vaccinationof neonates
EA007811B1 (ru) * 2002-05-16 2007-02-27 Бавариан Нордик А/С Межгенные области, используемые в качестве инсерционных сайтов в геноме модифицированного вируса коровьей оспы анкара (mva)
JP2005537793A (ja) * 2002-09-05 2005-12-15 バヴァリアン・ノルディック・アクティーゼルスカブ 無血清条件下で初代細胞を培養する方法及びウイルスを増幅させる方法
WO2004056977A1 (en) * 2002-12-13 2004-07-08 Aventis Pasteur, Inc. Production of alvac on avian embryonic stem cells
CN1980571A (zh) * 2003-01-24 2007-06-13 阿维季尼克斯股份有限公司 禽类及禽蛋中表达的外源蛋白质
US7262027B2 (en) * 2003-03-14 2007-08-28 Medical College Of Ohio Polypeptide and DNA immunization against Coccidioides spp. infections
EP1606419A1 (en) 2003-03-18 2005-12-21 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
AU2004249191B2 (en) 2003-06-13 2011-01-06 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
NZ570709A (en) 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
CA2545886A1 (en) 2003-11-13 2005-06-02 University Of Georgia Research Foundation, Inc. Methods of characterizing infectious bursal disease virus
JP2007525217A (ja) 2004-02-19 2007-09-06 ザ ガバナーズ オブ ザ ユニバーシティー オブ アルバータ レプチンプロモーター多型及びその使用
US20080274140A1 (en) * 2004-11-19 2008-11-06 David B Weiner Vaccines and Methods for Using the Same
WO2006056487A2 (en) * 2004-11-24 2006-06-01 Theraptosis S.A. Peptides useful as dual caspase-2/-6 inhibitors and their biological applications
CA2605629C (en) 2005-04-25 2012-06-26 Merial Limited Nipah virus vaccines
CN101563096A (zh) * 2005-07-28 2009-10-21 辉瑞产品公司 疫苗施用方法、新猫杯状病毒、及抗猫细小病毒和猫疱疹病毒的动物免疫方法
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
CA2629522A1 (en) 2005-11-14 2007-05-18 Merial Limited Gene therapy for renal failure
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
US7745158B2 (en) * 2005-12-14 2010-06-29 Kimberly-Clark Worldwide, Inc. Detection of secreted aspartyl proteases from Candida species
US8178660B2 (en) 2006-01-13 2012-05-15 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics using codon optimized IL-15 and methods for using the same
WO2007082105A2 (en) 2006-01-16 2007-07-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chlamydia vaccine
BRPI0709282B8 (pt) 2006-03-29 2021-05-25 Merial Ltd vacina contra estreptococos
US20090060947A1 (en) * 2006-05-19 2009-03-05 Sanofi Pasteur, Inc. Immunological compositions
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
DK2049559T3 (da) 2006-07-28 2013-03-25 Univ Pennsylvania Forbedrede HPV vacciner
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
CA2671570A1 (en) * 2007-01-26 2008-07-31 Synageva Biopharma Corp. Transgene expression in avians
MX2009011851A (es) 2007-05-02 2010-03-04 Merial Ltd Plasmidos de dna que tienen expresion y estabilidad mejoradas.
TW200907058A (en) 2007-05-30 2009-02-16 Wyeth Corp Raccoon poxvirus expressing rabies glycoproteins
US20090246226A1 (en) * 2008-03-28 2009-10-01 Zeon Corporation Avian vaccines possessing a positive marker gene
CN107083391A (zh) * 2008-04-04 2017-08-22 宾夕法尼亚大学托管会 屈曲病毒蛋白共有序列、编码该屈曲病毒蛋白共有序列的核酸分子和组合物及其使用方法
CA2720168C (en) 2008-04-04 2024-04-30 David B. Weiner Vaccines and immunotherapeutics using il-28 and compositions and methods of using the same
EP2283035B1 (en) 2008-05-08 2015-07-29 Merial Limited Leishmania vaccine using sand fly salivary immunogen
WO2010050939A1 (en) 2008-10-29 2010-05-06 The Trustees Of The University Of Pennsylvania Improved hcv vaccines and methods for using the same
US8921536B2 (en) 2008-10-29 2014-12-30 The Trustees Of The University Of Pennsylvania HCV vaccines and methods for using the same
US9050287B2 (en) 2009-01-23 2015-06-09 The Trustees Of The University Of Pennsylvania Vaccines for human papilloma virus and methods for using the same
CA2653478A1 (en) * 2009-01-23 2010-07-23 Gregg Martin Automated wash system for industrial vehicles
US20100192236A1 (en) * 2009-01-28 2010-07-29 University Of South Carolina Modulation of Delta Opioid Receptor Expression
KR101715418B1 (ko) 2009-04-03 2017-03-10 메리얼 인코포레이티드 뉴캐슬 질환 바이러스-벡터를 이용한 조류 백신
US20100284977A1 (en) * 2009-04-28 2010-11-11 University Of South Carolina Expression of Anti-Nociceptive Compounds from Endogenously Regulated Promoters
WO2010127115A1 (en) 2009-04-30 2010-11-04 Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) Modified immunization vectors
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
EP2477659A4 (en) 2009-09-14 2014-01-15 Univ Pennsylvania VACCINES AND IMMUNOTHERAPEUTICS WITH IL-15 RECEPTOR ALPHA AND / OR NUCLEIC ACID MOLECULES CODED THEREOF AND METHOD FOR THEIR USE
WO2011054011A2 (en) 2009-11-02 2011-05-05 The Trustees Of The University Of Pennsylvania Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
EP2539354B1 (en) 2010-02-08 2017-04-05 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same
US9109007B2 (en) 2010-08-18 2015-08-18 Purdue Pharma L.P. MHC-I restricted epitopes containing non-natural amino acid residues
PL2611460T3 (pl) 2010-08-31 2017-02-28 Merial, Inc. Szczepionki przeciw herpeswirusom przenoszone z pomocą wirusa choroby newcastle
AR083533A1 (es) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
KR101939150B1 (ko) 2010-11-12 2019-01-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 공통 전립선 항원, 이것을 암호화하는 핵산 분자, 그리고 이것을 포함하는 백신 및 용도
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
CN107090463A (zh) 2011-01-31 2017-08-25 宾夕法尼亚大学托管会 编码新型疱疹抗原的核酸分子、包含所述核酸分子的疫苗及其使用方法
US9238679B2 (en) 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
CA2827080C (en) 2011-02-11 2022-09-20 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same
US20140296248A1 (en) 2011-04-04 2014-10-02 Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
WO2012138789A2 (en) 2011-04-04 2012-10-11 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
US9216213B2 (en) 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
AP2013007180A0 (en) 2011-04-25 2013-10-31 Advanced Bioscience Lab Inc Truncated HIV envelope proteins (ENV), methods andcompositions related thereto
ES2674439T3 (es) 2011-06-01 2018-06-29 Merial, Inc. Administración sin aguja de vacunas contra el VSRRP
EP2731628B1 (en) 2011-07-11 2019-09-04 Inovio Pharmaceuticals, Inc. Dna vaccine against lassa virus
PL2734230T3 (pl) 2011-07-20 2019-07-31 Merial Limited Rekombinowana szczepionka przeciwko wirusowi białaczki kotów zawierająca zoptymalizowany gen otoczki wirusa białaczki kotów
EA031229B1 (ru) 2011-08-12 2018-12-28 Мериал, Инк. Способ витрификации биологического материала
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
WO2013033092A2 (en) 2011-09-03 2013-03-07 Boehringer Ingelheim Vetmedica Gmbh Streptococcus suis pilus antigens
CA3161127A1 (en) 2011-10-12 2013-04-18 The Trustees Of The University Of Pennsylvania Vaccines for human papilloma virus and methods for using the same
KR20140084236A (ko) 2011-10-24 2014-07-04 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 hcv 백신 및 이것을 사용하는 방법
CA2858884A1 (en) 2011-12-12 2013-06-20 The Trustees Of The University Of Pennsylvania Proteins comprising mrsa pbp2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat mrsa infections
EP3336096A1 (en) 2011-12-12 2018-06-20 The Trustees Of The University Of Pennsylvania Compositions, comprising improved il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
NZ700470A (en) * 2012-03-20 2016-04-29 Merial Inc Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein c and uses thereof
WO2013155205A1 (en) 2012-04-10 2013-10-17 The Trustees Of The University Of Pennsylvania Human respiratory syncytial virus concensus antigens, nucleic acid constructs and vaccines made thereform, and methods of using same
EP2958586B1 (en) 2013-02-21 2018-09-05 Boehringer Ingelheim Vetmedica GmbH H5 proteins of h5n1 influenza virus for use as a medicament
JP6517779B2 (ja) 2013-03-12 2019-05-22 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスの改良型ワクチンおよびその使用方法
EP2968514A1 (en) 2013-03-12 2016-01-20 Merial, Inc. Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof
BR112015022582B1 (pt) 2013-03-15 2024-01-09 The Trustees Of The University Of Pennsylvania Molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
EA034110B1 (ru) 2013-03-15 2019-12-27 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Противораковые вакцины и способы лечения с их применением
MX376715B (es) 2014-04-03 2025-03-07 Boehringer Ingelheim Animal Health Usa Inc Vacuna contra el virus de la diarrea epidemica porcina.
WO2016073410A1 (en) 2014-11-03 2016-05-12 Merial, Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
NZ738957A (en) 2015-06-23 2019-09-27 Boehringer Ingelheim Animal Health Usa Inc Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof
UA124140C2 (uk) 2015-08-31 2021-07-28 Бьорінгер Інгельхайм Ветмедіка Гмбх Пестивірусна вакцина проти вродженого тремору поросят
JP2018526454A (ja) 2015-09-16 2018-09-13 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド ブタコレラ菌−ネズミチフス菌ワクチン
HUE072083T2 (hu) 2016-09-20 2025-10-28 Boehringer Ingelheim Vetmedica Gmbh Új promóterek
CN110072546B (zh) 2016-09-20 2023-10-31 勃林格殷格翰动物保健有限公司 新的猪流感疫苗
CN109715204B (zh) 2016-09-20 2023-08-22 勃林格殷格翰动物保健有限公司 新的ehv插入位点orf70
BR112019005511A2 (pt) 2016-09-20 2019-10-01 Boehringer Ingelheim Vetmedica Gmbh vetores de adenovírus canino
PT3534945T (pt) 2016-11-03 2025-06-30 Boehringer Ingelheim Vetmedica Gmbh Vacina contra o parvovírus suíno
MX380632B (es) 2016-11-03 2025-03-12 Boehringer Ingelheim Vetmedica Gmbh Vacuna contra el parvovirus porcino y el virus del síndrome respiratorio y reproductivo porcino y métodos de producción de esta.
AU2018212843A1 (en) 2017-01-30 2019-06-27 Boehringer Ingelheim Animal Health USA Inc. Porcine coronavirus vaccines
EP3651797A1 (en) 2017-07-12 2020-05-20 Boehringer Ingelheim Animal Health USA Inc. Senecavirus a immunogenic compositions and methods thereof
EP3675903A1 (en) 2017-09-23 2020-07-08 Boehringer Ingelheim Vetmedica GmbH Paramyxoviridae expression system
WO2019092027A1 (en) 2017-11-09 2019-05-16 Boehringer Ingelheim Vetmedica Gmbh Sapelovirus immunogenic compositions and uses thereof
EP3723812A4 (en) 2017-12-13 2022-02-16 Inovio Pharmaceuticals, Inc. ANTI-MUC16 CANCER VACCINES AND USES THEREOF
BR112020011443A2 (pt) 2017-12-13 2020-12-01 Inovio Pharmaceuticals, Inc. molécula de ácido nucleico e seu uso, vetor e seu uso, composição, proteína e vacina
BR112020010499A2 (pt) 2017-12-13 2020-11-24 Inovio Pharmaceuticals, Inc. vacinas de câncer de alvo de mesotelina e usos das mesmas
CN111479585A (zh) 2017-12-13 2020-07-31 艾诺奥医药品有限公司 靶向boris的癌症疫苗和其用途
RU2711907C2 (ru) * 2017-12-22 2020-01-23 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова) Рекомбинантный белок, содержащий антигенно-значимые фрагменты белков вируса гепатита Е, используемый в тест-системах для серодиагностики гепатита Е (варианты)
TW201942355A (zh) 2018-02-23 2019-11-01 德商百靈佳殷格翰維美迪加股份有限公司 表現外源貓副黏液病毒基因之重組病毒載體系統及自其製備之疫苗
WO2019179966A1 (en) 2018-03-19 2019-09-26 Boehringer Ingelheim Vetmedica Gmbh Ehv insertion site ul43
KR20200132958A (ko) 2018-03-19 2020-11-25 베링거잉겔하임베트메디카게엠베하 불활성화된 ul18 및/또는 ul8을 갖는 신규한 ehv
WO2019191005A1 (en) 2018-03-26 2019-10-03 Boehringer Ingelheim Animal Health USA Inc. Method of producing an immunogenic composition
KR102879825B1 (ko) 2018-09-20 2025-11-03 베링거잉겔하임베트메디카게엠베하 변형된 pedv 스파이크 단백질
EP3852800A1 (en) 2018-09-20 2021-07-28 Boehringer Ingelheim Vetmedica GmbH Intranasal vector vaccine against porcine epidemic diarrhea
EP4100420A1 (en) 2020-02-06 2022-12-14 Boehringer Ingelheim Vetmedica GmbH Polypeptides useful for detecting anti-rhabdovirus antibodies
CA3195910A1 (en) 2020-10-05 2022-04-14 Boehringer Ingelheim Vetmedica Gmbh Fusion protein useful for vaccination against rotavirus
EP4225361A1 (en) 2020-10-05 2023-08-16 Boehringer Ingelheim Animal Health USA Inc. Fusion protein comprising circoviridae capsid protein, and chimeric virus-like particles composed thereof
US20240050555A1 (en) 2022-04-05 2024-02-15 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition useful for vaccination against rotavirus
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1061898A (en) 1963-03-07 1967-03-15 Philips Electronic Pharma Method for protecting dogs against canine distemper
US4722848A (en) * 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) * 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
JPH0795954B2 (ja) * 1982-11-30 1995-10-18 アメリカ合衆国 外来性遺伝子発現のためのポックスウイルス組換え体の製造方法
EP0162738A1 (en) 1984-04-09 1985-11-27 MOLECULAR GENETICS RESEARCH & DEVELOPMENT LIMITED PARTNERSHIP Production of pseudorabies virus subunit vaccines
US5242829A (en) * 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
EP0261940A3 (en) * 1986-09-23 1989-07-05 Applied Biotechnology, Inc. Pseudorabies vaccines and dna vectors for recombination with pox viruses
AU605567B2 (en) * 1987-03-11 1991-01-17 Nippon Zeon Co., Ltd. Recombinant avipoxvirus
EP0297924A3 (en) * 1987-07-01 1990-07-11 City Of Hope Recombinant vaccinia virus expressing hsv 1 gb
DE10399031I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
WO1990001546A1 (en) * 1988-08-05 1990-02-22 Applied Biotechnology, Inc. Equine herpesvirus-1 vaccine
IE71643B1 (en) 1990-11-20 1997-02-26 Virogenetics Corp A recombinant poxviral vaccine for canine distemper

Also Published As

Publication number Publication date
GB9120655D0 (en) 1991-11-27
NL9020677A (nl) 1992-02-03
CH682671A5 (fr) 1993-10-29
JP3083839B2 (ja) 2000-09-04
BE1004369A5 (fr) 1992-11-10
GB2246784B (en) 1993-04-28
DK174391A (da) 1991-12-12
AU625623B2 (en) 1992-07-16
IT9020063A1 (it) 1991-10-17
US6183750B1 (en) 2001-02-06
CA2014465A1 (en) 1990-10-17
IT9020063A0 (it) 1990-04-17
IT1241119B (it) 1993-12-29
ATA902590A (de) 1998-10-15
US5338683A (en) 1994-08-16
IE901380L (en) 1990-10-17
US5482713A (en) 1996-01-09
IE61098B1 (en) 1994-09-21
KR920700289A (ko) 1992-02-19
JPH04505248A (ja) 1992-09-17
AU5552090A (en) 1990-11-16
JP3246735B2 (ja) 2002-01-15
DE4090565C2 (de) 2000-03-09
DK174391D0 (da) 1991-10-15
FR2647808A1 (fr) 1990-12-07
NL195016C (nl) 2003-06-10
WO1990012882A1 (en) 1990-11-01
FR2647808B1 (fr) 1995-03-03
LU88018A1 (fr) 1992-03-11
JP2000157292A (ja) 2000-06-13
AT405184B (de) 1999-06-25
CA2014465C (en) 1999-06-15
GB2246784A (en) 1992-02-12
DK176464B1 (da) 2008-03-31

Similar Documents

Publication Publication Date Title
FR2641692B1 (enExample)
DK0433255T3 (enExample)
FR2644892B1 (enExample)
FR2641749B1 (enExample)
DE4090565T (enExample)
DE4091597T (enExample)
DE4091606T (enExample)
FR2645293B1 (enExample)
DE4090852T (enExample)
DE4092018T (enExample)
DE3991793T1 (enExample)
FR2653389B1 (enExample)
DE4092217T (enExample)
FR2641828B1 (enExample)
DE4091474T (enExample)
DE4091687T (enExample)
DK0491704T3 (enExample)
FR2644164B1 (enExample)
FR2644153B1 (enExample)
FR2644634B1 (enExample)
DE4092151T1 (enExample)
DE4090021T (enExample)
DE4092184T (enExample)
FR2643929B1 (enExample)
FR2644734B1 (enExample)